bladder cancer diagnostic development

With years of experience in developing antibodies for analytical research and diagnostic applications, Creative Biolabs specializes in custom antibody and assay development for the diagnosis of a variety of diseases and infections. Particularly, we provide high-quality in vitro diagnostic (IVD) antibody development services for the diagnosis of different cancers, such as bladder cancer.

Introduction of Bladder Cancer

Bladder cancer is the commonest malignancy of the urinary tract, accounting for 7 percent of all cancers in men and 2 percent of those in women. The main symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. Although the accurate cause remains unclear, risk factors that may contribute to its development include cigarette smoking, occupational exposure to chemicals such as aniline dyes and aromatic amines, consumption of analgesics containing phenacetin, chronic infection or irritation of the bladder, and chemotherapeutic agents such as cyclophosphamide. Over 90% of malignant tumors of the bladder are 'urothelial' transitional cell carcinoma (TCC). Less common forms of bladder cancer include squamous cell carcinoma, adenocarcinoma, and neuroendocrine tumors. The grading and staging of bladder cancer use the TNM (tumor, nodes, metastases) classification system, which provides important information for disease prognosis and prediction.

Learn more: bladder cancer diagnostic development